Joan Merrill to Male
This is a "connection" page, showing publications Joan Merrill has written about Male.
Connection Strength
2.124
-
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med. 2022 03 17; 386(11):1034-1045.
Score: 0.068
-
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021 11 03; 60(11):5379-5389.
Score: 0.066
-
Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020 10 01; 59(10):2930-2938.
Score: 0.061
-
Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity. Health Qual Life Outcomes. 2019 Jun 07; 17(1):99.
Score: 0.056
-
The Spectrum of Health Domains Important to Lupus Patients Early Development of a Disease Activity Patient Reported Outcome. Bull Hosp Jt Dis (2013). 2019 Mar; 77(2):92-98.
Score: 0.055
-
Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World Clinicians. Arthritis Care Res (Hoboken). 2018 07; 70(7):1058-1063.
Score: 0.052
-
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889.
Score: 0.051
-
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2018 02; 70(2):266-276.
Score: 0.051
-
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol. 2017 06; 69(6):1257-1266.
Score: 0.049
-
Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017 12; 185:3-9.
Score: 0.047
-
Impact of heart rate variability, a marker for cardiac health, on lupus disease activity. Arthritis Res Ther. 2016 09 02; 18:197.
Score: 0.046
-
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb; 75(2):332-40.
Score: 0.043
-
Connective tissue diseases: Is SLE many single-organ diseases or an overlapping spectrum? Nat Rev Rheumatol. 2015 Jul; 11(7):385-6.
Score: 0.042
-
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014 Feb; 66(2):379-89.
Score: 0.039
-
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct; 64(10):3364-73.
Score: 0.035
-
Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011 Oct; 70(10):1726-32.
Score: 0.033
-
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov; 70(11):1905-13.
Score: 0.032
-
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct; 62(10):3077-87.
Score: 0.031
-
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33.
Score: 0.029
-
Bone marrow edema is the most specific finding for rheumatoid arthritis (RA) on noncontrast magnetic resonance imaging of the hands and wrists: a comparison of patients with RA and healthy controls. J Rheumatol. 2010 Feb; 37(2):265-74.
Score: 0.029
-
Regulation of the vasculature: clues from lupus. Curr Opin Rheumatol. 2002 Sep; 14(5):504-9.
Score: 0.017
-
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 07; 81(7):951-961.
Score: 0.017
-
Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Care Res (Hoboken). 2022 04; 74(4):638-647.
Score: 0.017
-
Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 03; 81(3):370-378.
Score: 0.017
-
Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis Rheumatol. 2021 12; 73(12):2293-2302.
Score: 0.016
-
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care Res (Hoboken). 2021 12; 73(12):1789-1795.
Score: 0.016
-
Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology (Oxford). 2021 10 02; 60(10):4737-4747.
Score: 0.016
-
Which antiphospholipid antibody tests are most useful? Rheum Dis Clin North Am. 2001 Aug; 27(3):525-49.
Score: 0.016
-
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2020 12; 72(12):1800-1808.
Score: 0.015
-
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. Lupus Sci Med. 2020 10; 7(1).
Score: 0.015
-
Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis Rheumatol. 2020 10; 72(10):1734-1740.
Score: 0.015
-
Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. J Am Acad Dermatol. 2021 Jun; 84(6):1562-1567.
Score: 0.015
-
Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020 12; 146(6):1419-1433.
Score: 0.015
-
Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. Lupus Sci Med. 2020; 7(1):e000360.
Score: 0.015
-
Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Rheumatol. 2020 04; 72(4):658-666.
Score: 0.015
-
Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Ann Rheum Dis. 2020 03; 79(3):356-362.
Score: 0.015
-
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2020 01; 72(1):67-77.
Score: 0.014
-
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J Autoimmun. 2020 01; 106:102340.
Score: 0.014
-
Immunologic findings precede rapid lupus flare after transient steroid therapy. Sci Rep. 2019 06 13; 9(1):8590.
Score: 0.014
-
Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care Res (Hoboken). 2019 07; 71(7):893-902.
Score: 0.014
-
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 07; 71(7):1125-1134.
Score: 0.014
-
Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 08; 71(8):1297-1307.
Score: 0.014
-
Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. J Rheumatol. 2020 01; 47(1):72-81.
Score: 0.014
-
Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2019 02; 71(2):281-289.
Score: 0.014
-
Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. J Rheumatol. 2019 05; 46(5):492-500.
Score: 0.014
-
Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum Mol Genet. 2018 11 01; 27(21):3813-3824.
Score: 0.013
-
Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care Res (Hoboken). 2018 10; 70(10):1478-1487.
Score: 0.013
-
A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Hum Mol Genet. 2018 07 01; 27(13):2392-2404.
Score: 0.013
-
Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Arthritis Rheumatol. 2018 07; 70(7):1071-1076.
Score: 0.013
-
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology (Oxford). 2018 04 01; 57(4):677-687.
Score: 0.013
-
Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Res Ther. 2017 12 22; 19(1):287.
Score: 0.013
-
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. J Rheumatol. 2018 04; 45(4):456-464.
Score: 0.013
-
Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls. Arthritis Care Res (Hoboken). 2017 12; 69(12):1780-1788.
Score: 0.013
-
High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol. 1997 Jun; 24(6):1083-8.
Score: 0.012
-
Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. Arthritis Rheumatol. 2017 04; 69(4):785-790.
Score: 0.012
-
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. Arthritis Rheumatol. 2017 03; 69(3):643-654.
Score: 0.012
-
The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017 Sep; 26(10):1051-1059.
Score: 0.012
-
Pathways of impending disease flare in African-American systemic lupus erythematosus patients. J Autoimmun. 2017 03; 78:70-78.
Score: 0.012
-
Anifrolumab, an Anti-Interferon-a Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 02; 69(2):376-386.
Score: 0.012
-
Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity. Arthritis Rheumatol. 2016 10; 68(10):2492-502.
Score: 0.012
-
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017 Mar; 76(3):534-542.
Score: 0.012
-
A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis Rheumatol. 2016 08; 68(8):1932-44.
Score: 0.011
-
Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. Arthritis Care Res (Hoboken). 2016 Apr; 68(4):534-43.
Score: 0.011
-
Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov; 75(11):1909-1916.
Score: 0.011
-
Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production. Ann Rheum Dis. 2016 Nov; 75(11):2007-2013.
Score: 0.011
-
The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016 Feb; 55(2):252-62.
Score: 0.011
-
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015 Aug 20; 17:215.
Score: 0.011
-
Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2015 Jul; 67(7):1837-47.
Score: 0.011
-
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016 Jan; 75(1):196-202.
Score: 0.011
-
Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura. PLoS One. 2015; 10(2):e0117614.
Score: 0.010
-
Genetic association of CD247 (CD3?) with SLE in a large-scale multiethnic study. Genes Immun. 2015 Mar; 16(2):142-50.
Score: 0.010
-
Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. Arthritis Care Res (Hoboken). 2015 Jan; 67(1):128-35.
Score: 0.010
-
Disease activity in systemic lupus erythematosus correlates with expression of the transcription factor AT-rich-interactive domain 3A. Arthritis Rheumatol. 2014 Dec; 66(12):3404-12.
Score: 0.010
-
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov; 66(11):1653-61.
Score: 0.010
-
The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Hum Mol Genet. 2015 Jan 15; 24(2):582-96.
Score: 0.010
-
25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. Arthritis Care Res (Hoboken). 2014 Aug; 66(8):1167-76.
Score: 0.010
-
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015 Sep; 74(9):1706-13.
Score: 0.010
-
Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. Am J Hum Genet. 2014 Apr 03; 94(4):586-98.
Score: 0.010
-
American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. J Rheumatol. 2014 May; 41(5):875-80.
Score: 0.010
-
Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2015 Aug; 74(8):1530-6.
Score: 0.010
-
End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014 Feb; 66(2):390-6.
Score: 0.010
-
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013 Nov; 65(11):2887-97.
Score: 0.009
-
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb; 41(2):300-9.
Score: 0.009
-
Trans-ancestral studies fine map the SLE-susceptibility locus TNFSF4. PLoS Genet. 2013; 9(7):e1003554.
Score: 0.009
-
Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013 May; 40(5):579-89.
Score: 0.009
-
Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Res Ther. 2013 Mar 20; 15(2):R44.
Score: 0.009
-
Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther. 2013; 15(6):R212.
Score: 0.009
-
Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum. 2012 Nov; 64(11):3695-705.
Score: 0.009
-
Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum. 2012 Nov; 64(11):3687-94.
Score: 0.009
-
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013 Aug; 72(8):1308-14.
Score: 0.009
-
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov; 71(11):1833-8.
Score: 0.009
-
A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. Genes Immun. 2012 Jul; 13(5):380-7.
Score: 0.008
-
Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum. 2012 Aug; 42(1):56-65.
Score: 0.008
-
Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis. 2012 Sep; 71(9):1502-9.
Score: 0.008
-
Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet. 2012 Apr 06; 90(4):648-60.
Score: 0.008
-
Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity. J Autoimmun. 2012 May; 38(2-3):J216-22.
Score: 0.008
-
Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. Arthritis Rheum. 2012 Feb; 64(2):485-92.
Score: 0.008
-
Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis. J Rheumatol. 2012 Mar; 39(3):510-5.
Score: 0.008
-
Evaluation of TRAF6 in a large multiancestral lupus cohort. Arthritis Rheum. 2012 Jun; 64(6):1960-9.
Score: 0.008
-
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012 Jan; 64(1):132-7.
Score: 0.008
-
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30.
Score: 0.008
-
Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Ann Rheum Dis. 2012 May; 71(5):694-9.
Score: 0.008
-
Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK. Ann Rheum Dis. 2012 Jan; 71(1):136-42.
Score: 0.008
-
Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis Rheum. 2011 Sep; 63(9):2755-63.
Score: 0.008
-
Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum. 2011 Aug; 63(8):2396-406.
Score: 0.008
-
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis. 2011 Oct; 70(10):1752-7.
Score: 0.008
-
SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011 Jun; 70(6):961-7.
Score: 0.008
-
Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet. 2011 Mar; 43(3):253-8.
Score: 0.008
-
Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011 Jun; 12(4):270-9.
Score: 0.008
-
Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet. 2011 Jan 07; 88(1):83-91.
Score: 0.008
-
The lupus family registry and repository. Rheumatology (Oxford). 2011 Jan; 50(1):47-59.
Score: 0.008
-
TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2010; 12(4):R146.
Score: 0.008
-
The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol. 2010; 2010.
Score: 0.008
-
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Jun; 62(6):881-7.
Score: 0.007
-
ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann Rheum Dis. 2010 Jul; 69(7):1329-32.
Score: 0.007
-
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78.
Score: 0.007
-
Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51.
Score: 0.007
-
A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum. 2009 Aug; 60(8):2402-7.
Score: 0.007
-
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010 Mar; 69(3):529-35.
Score: 0.007
-
Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum. 2009 Apr; 60(4):1076-84.
Score: 0.007
-
High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. Arthritis Rheum. 2009 Apr; 60(4):1085-95.
Score: 0.007
-
Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2009 Apr 14; 106(15):6256-61.
Score: 0.007
-
Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology (Oxford). 2009 May; 48(5):513-9.
Score: 0.007
-
Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med (Maywood). 2009 Mar; 234(3):354-60.
Score: 0.007
-
Evaluation of imputation-based association in and around the integrin-alpha-M (ITGAM) gene and replication of robust association between a non-synonymous functional variant within ITGAM and systemic lupus erythematosus (SLE). Hum Mol Genet. 2009 Mar 15; 18(6):1171-80.
Score: 0.007
-
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
Score: 0.007
-
Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 2008 May 15; 59(5):721-9.
Score: 0.006
-
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum. 2008 Mar; 58(3):843-53.
Score: 0.006
-
Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis. 2008 Apr; 67(4):458-61.
Score: 0.006
-
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007 Jan; 56(1):265-73.
Score: 0.006
-
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24; 353(21):2219-28.
Score: 0.005
-
Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol. 2004 Dec; 31(12):2390-4.
Score: 0.005
-
Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol. 2004 Jan; 121(1):142-9.
Score: 0.005
-
Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance. Thromb Haemost. 2003 Oct; 90(4):636-41.
Score: 0.005
-
IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol. 2003 Jun-Dec; 10(2-4):203-11.
Score: 0.005
-
Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome. Arthritis Rheum. 2003 Mar; 48(3):737-45.
Score: 0.005
-
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec; 46(12):3251-8.
Score: 0.004
-
A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome. Arthritis Rheum. 1999 Aug; 42(8):1655-61.
Score: 0.004
-
Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus. 1998; 7(5):355-60.
Score: 0.003